Researchers trial inhaled versions of Oxford and Imperial COVID-19 vaccine candidates

Tuesday, 15 Sep, 2020

In a statement, Oxford University said: "The ongoing randomised controlled clinical trials of the Oxford coronavirus vaccine CHAdOx1 nCoV-19 will resume across all United Kingdom clinical trial sites".

AstraZeneca paused global trials temporarily last week after an unexplained illness in a participant in Britain.

The statement said the UK Medicines Health Regulatory Authority approved trials to resume after an independent review of data "triggered a voluntary pause" on September 6.

Oxford said that globally some 18,000 people have received its vaccine so far.

Dr Al Kaabi said health authorities had taken every precaution to ensure the quality and safety of the vaccine trial.

Cambridge-based AstraZeneca's shares had risen about 11% this year up to their Friday close of 8,429 pence, giving the pharmaceutical giant a market capitalisation of 111 billion pounds ($142 billion). Subsequent investigations then consider whether the drug, or vaccine, being tested can be linked to the negative health condition. The MHRA concurred and gave the green light for the trial to restart.

"AstraZeneca and the University of Oxford, as the trial sponsor, can not disclose further medical information", AstraZeneca said in a statement. If the trials are successful and the necessary approvals were obtained, these nine vaccines will come before the end of the year.

"We are committed to the safety of our participants and the highest standards of conduct in our studies and will continue to monitor safety closely", they added.

The fact that some pharmaceutical companies delegate the risks associated with their vaccines to countries which buy them raises additional questions, the RDIF chief said. "The investigators need to go through the process of trying to work out what may have happened in this situation before progressing with this trial". News that the trial is resuming comes four days after the disclosure that it had been paused because of a suspected serious adverse reaction in a participant.

The Russian group of companies R-Pharm has agreed with AstraZeneca on the production of a vaccine against COVID-19, Alexey Repik, chairman of the board of directors of R-Pharm, said on the air of the state channel Russia-24 in July. Here's how top drugmakers see the race for a cure playing out in 2020 and 2021 and when the first shots might be available.